SCHEMBL31279069

SCHEMBL31279069

CC(=O)C1CCN(C(=O)OC(C)(C)C)CC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.46
▸ RECQL P46063 1/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GPR119 Q8TDV5 5/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ PTPN2 P17706 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PTPN6 P29350 1/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ STS P08842 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26347371 0.88 HPGD (0.46) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL27212149 0.87 HPGD (0.44) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL17723305 0.85 EPHX1 (0.45) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL29915412 0.84 HPGD (0.44) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL2777507 0.81 HPGD (0.48) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL16356225 0.81 HPGD (0.48) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL14671956 0.81 HPGD (0.48) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL14671811 0.81 HPGD (0.48) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL4176004 0.80 HPGD (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL4180649 0.80 HPGD (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022123-A1 Methods of Making Modified BTK Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2026-01-22 — — US disclosed
CN-119343340-A Methods of preparing modified BTK inhibitors 普林斯匹亚生物制药公司 2025-01-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022123-A1 Methods of Making Modified BTK Inhibitors BTK, TEC, SYK HPGD 4026/4885RECQL 3620/4885EPHX1 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback